Drug intelligence / Profile preview

M1069

Development stage: Discontinued
Lead developer: Merck KGaA
Modality: Small Molecules
Administration: Oral

Overview

M1069 is an orally available, selective small molecule antagonist of the adenosine A2A and A2B receptors. It was jointly discovered by Domain Therapeutics and Merck KGaA for use in immuno-oncology. M1069 counteracts the immune-suppressive mechanisms mediated by adenosine in the tumor microenvironment, thereby exhibiting anti-tumor activity. The drug entered phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and early efficacy in patients with metastatic or locally advanced unresectable solid tumors. Development was discontinued after a portfolio review[1][2][3][4].

Other names: adenosine receptor a2a/a2b antagonist m1069

Targets

ADORA2B (Adenosine A2B receptor)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on M1069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M1069.

Explore the full profile